Medicare weight-loss drugs coverage has become a contentious topic after the recent announcement from the Centers for Medicare and Medicaid Services (CMS).The Biden Administration's proposal to include medications such as Wegovy and Zepbound, both effective obesity treatments, has been halted without further explanation.